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Aberrant Notch and Wnt signalling are known drivers of cholangiocarcinoma (CCA) but the 29 
underlying factors that initiate and maintain these pathways are not known. Here we show 30 
that the PRH/HHEX transcription factor forms a positive transcriptional feedback loop with 31 
Notch3 that is critical in CCA. PRH/HHEX expression was elevated in CCA and depletion of 32 
PRH reduced CCA tumour growth in a xenograft model. Overexpression of PRH in primary 33 
human biliary epithelial cells was sufficient to increase cell proliferation and produce an 34 
invasive phenotype. Interrogation of the gene networks regulated by PRH and Notch3 35 
revealed that unlike Notch3, PRH directly activated canonical Wnt signalling. These data 36 
indicate that hyperactivation of Notch and Wnt signalling is independent of the underlying 37 
mutational landscape and has a common origin in dysregulation of PRH. Moreover, they 38 
suggest new therapeutic options based on the dependence of specific Wnt, Notch, and 39 
CDK4/6 inhibitors on PRH activity. 40 
Significance 41 
The PRH/HHEX transcription factor is an oncogenic driver in cholangiocarcinoma that 42 
confers sensitivity to CDK4/6 inhibitors. 43 
 44 
Keywords: cholangiocarcinoma, bile duct, biliary epithelial cells, cholangiocyte, HHEX, 45 
PRH, Notch, Wnt, epithelial-mesenchymal transition 46 
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Cholangiocarcinoma (CCA) is a tumour of the bile duct epithelium with an unmet clinical 49 
need as this disease is usually advanced at diagnosis. For non-resectable disease median 50 
survival is less than 12 months and 5-year survival is around 2% (1). New treatment options 51 
and markers that allow early detection and/or inform personalised cancer treatment are 52 
therefore urgently needed. Risk factors for CCA include viral infection (Hepatitis B and C), 53 
liver fluke infection, primary sclerosing cholangitis (PSC), cholestasis (loss of bile flow), and 54 
exposure to dietary toxins or metabolites, all of which lead to inflammation in and around the 55 
biliary tree. Chronic inflammation can provoke uncontrolled wound-healing responses 56 
involving the generation of DNA-damaging reactive oxygen and nitrogen species, activation 57 
of immune cells (particularly macrophages) and stroma, and aberrant activation of autocrine 58 
signalling, as well as activation of signalling pathways that promote epithelial-mesenchymal 59 
transition (EMT) and angiogenesis. All these events ultimately lead to cancer development 60 
and progression (2). Many of the dysregulated pathways involved in CCA are also involved 61 
in embryonic liver morphogenesis, such as the Wnt, TGFβ, Notch, Hedgehog and Hippo 62 
pathways. Several of these pathways (including Wnt and Notch) can transiently promote 63 
EMT or the acquisition of mesenchymal features, such as increased cell migration and matrix 64 
invasion or loss of the epithelial cell-cell adhesion molecule E-cadherin (3, 4). In many 65 
cancers including mammary cancers, EMT is associated with an increased proportion of 66 
tumour initiating cells (the so-called cancer stem cells or CSC) that show increased self-67 
renewal properties and increased chemoresistance (3). EMT and the CSC phenotype can be 68 
induced by any one of a common set of aberrantly expressed EMT transcription factors (e.g. 69 
Snail, Twist, Zeb) that, amongst many other things, directly repress the expression of E-70 
cadherin (reviewed (5)). CCA patient samples exhibit decreased E-cadherin expression and 71 
contain CSCs (6) suggesting that EMT may also be a feature of CCA.  72 
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Canonical Wnt signalling is critical for cell proliferation and contributes to the development 73 
of CCA in a mouse CCA carcinogenesis model (7, 8). In canonical Wnt signaling, Wnt 74 
ligands activate Frizzled family receptors and stabilise the β-catenin protein which then enters 75 
the nucleus and activates transcription of Wnt target genes through interaction with TCF/LEF 76 
family transcription factors and co-activators (4). β-catenin, by acting as both a co-activator 77 
for TCF/LEF transcription factors and a structural component of adherens junctions via 78 
interaction with E-cadherin, facilitates cross-talk between canonical Wnt signalling and cell-79 
cell adhesion. Although there are few mutations in Wnt signalling components in CCA there 80 
are high levels of nuclear -catenin in the majority of CCA (7, 9).  Importantly, 81 
pharmacological inhibition of Wnt signalling decreases CCA formation in mouse models (7).   82 
NOTCH signalling is also of central importance to the development of CCA (10). Notch 83 
signalling involves four transmembrane NOTCH receptors and two families of ligands, 84 
Serrate/Jagged (JAG-1, -2) and Delta-like (DLL-1, -3, -4), along with other proteins that 85 
transduce and regulate the signal. Upon ligand binding, Notch receptors are sequentially 86 
cleaved by an ADAM family protease and the γ-secretase protease complex. Cleavage 87 
releases the NOTCH intracellular domain (ICD) which interacts with the DNA binding 88 
protein RBP-J/CSL and MAML1 co-activator resulting in transcriptional activation of 89 
NOTCH target genes, including the HES and HEY family of genes encoding bHLH 90 
transcriptional repressors (reviewed in (11)). In hepatic regeneration models, Wnt and Notch 91 
signalling promote different cell fates; Notch signalling promotes biliary fate in Hepatic 92 
Progenitor Cells and Wnt signalling promotes hepatic specification (12). Dysregulation of 93 
Notch signalling in mouse hepatocytes through constitutive Notch1 ICD or Notch2 ICD 94 
expression can result in either hepatocellular carcinoma (HCC) or CCA depending on the co-95 
operating oncogene. NOTCH3 is not expressed in adult liver but Notch3 expression is 96 
elevated in CCA patient samples and knockout of Notch3 in a mouse model of CCA 97 
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abrogates tumour growth (10). Notch3 ICD is known to be a key driver of CCA in part 98 
through activation of PI3K/Akt signalling (10). However, it is not known which genes the 99 
Notch3 ICD regulates nor is the interplay between Notch3 ICD signalling and Wnt signalling 100 
understood.  101 
The Proline-Rich Homeodomain protein/Haematopoietically Expressed Homeobox 102 
(PRH/HHEX) protein is a transcription factor encoded by the HHEX gene that is required in 103 
the development of many tissue types including the liver and bile duct (reviewed (13)), where 104 
PRH regulates hepatic (HNF4a) and biliary (Onecut1) transcription factors, respectively (14). 105 
PRH plays a growth inhibitory role in hepatic regeneration (15) and when over-expressed in 106 
hepatocellular carcinoma cells PRH inhibited tumour growth in a mouse xenograft model 107 
(16, 17). PRH also exhibits tumour suppressive properties in other epithelial lineages and in 108 
some haematopoietic lineages (13). Similarly, in breast and prostate cells, PRH inhibits cell 109 
migration and loss or inactivation of PRH induces EMT-like changes in cell morphology and 110 
behaviour (18) and increases the proportion of CSC-like cells (19, 20). In stark contrast, PRH 111 
is involved in oncogenic transformation in at least two leukaemic subtypes in which 112 
cytogenetic rearrangements promote dysregulated PRH expression (21-23). As PRH 113 
potentiates Wnt signalling during early embryonic development (24) and early liver 114 
development (25) it is of interest to understand whether PRH plays a role in CCA and 115 
whether it is involved in regulating Wnt and Notch signalling . 116 
Here we show for the first time that PRH plays an essential role in the maintenance of CCA. 117 
We also demonstrate that PRH promotes multiple features of tumour initiation and spread in 118 
primary untransformed biliary epithelial cells (cholangiocytes) isolated from human liver. 119 
Our work shows that a PRH-Notch3 positive feedback loop is a novel driver of CCA as both 120 
proteins collaborate to promote Wnt signalling. Further we demonstrate that PRH expression 121 
levels can determine sensitivity or resistance to novel CCA chemotherapeutic strategies.  122 
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Materials and methods 123 
Cell culture and plasmids 124 
CCLP-1, CCSW-1, AKN-1, KKU-100 and KKU-M213 cells (26, 27) were grown in 125 
Dulbecco’s modified Eagle medium (DMEM) with L-glutamine (Sigma-Aldrich, D5796), 126 
supplemented with 10% FBS and MEM non-essential amino acids (Sigma-Aldrich, M1745). 127 
CCLP-1, CCSW-1, AKN-1 cells were authenticated in house by phenotyping using flow 128 
cytometry. KKU-100 and KKU-M213 (28) were obtained from the Japanese Cell Research 129 
Bank (JCRB1557 (KKU-213) and JCRB1568 (KKU-100)).  HuCCA-1 (29) and RmCCA-1 130 
(30) were kindly provided by the originators Prof. Stitaya Sirisinha and Assoc. Prof. 131 
Rutaiwan Tohtong respectively.  HuCCA-1 and RmCCA-1 were grown in Ham’s F12 132 
medium (Thermofisher IBR21041025) and supplemented with 10% FBS. All cell lines were 133 
mycoplasma tested every 3 months using EZ-PCR mycoplasma test kit (Biological 134 
Industries). Primary biliary epithelial cells were isolated and grown as previously described 135 
(31). Stable cell lines were generated by transfecting PRH shRNA in pRS (Origene, 136 
TR312464), Notch3 shRNA in pLKO (Sigma-Aldrich, TRCN0000363316), CDH1 cDNA in 137 
pCDNA3 (hE-cadherin-pcDNA3 was a gift from Barry Gumbiner, Addgene plasmid 138 
#45769), or EGFP-PRH-myc in pEGFP-C1. Transient PRH knockdowns were performed 139 
using 100 nM each of 4 HHEX targeted siRNAs (Qiagen, 1027416). pEGFP-C1-PRH-Myc 140 
was generated by insertion of the human PRH cDNA between EcoRI and KpnI sites in 141 
pEGFP-C1. PCR was used to generate a PstI-KpnI fragment that replaced PRH coding 142 
sequence and placed an in-frame Myc tag followed by a translation stop codon at the end of 143 
the PRH coding sequence. This creates a double-tagged protein. Stable transfectants were 144 
selected for vector integration using either puromycin (pRS, pLKO) or G418 (pcDNA3, 145 
pEGFP-C1). For transient over-expression, PRH was over-expressed either using an 146 
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adenoviral construct at MOI 50, or using pMUG1-myc-PRH (32). For transient Rb 147 
knockdown we used 100nM of Rb targeted siRNAs (Qiagen, 1027416). 148 
 149 
EdU incorporation 150 
Cells were plated at 10
4
 cells per well in 96-well plates, and EdU incorporation was measured 151 
after 24 hours. For inhibitor experiments, inhibitors were added at the time of plating. Click-152 
It EdU microplate kit (ThermoFisher, C10214) was used according to the manufacturer’s 153 
instructions with the exception of replacement of the fluorescent kit substrate with the 154 
colourimetric peroxidase substrate o-Phenylinediamine (Sigma-Aldrich, P9187) to improve 155 
signal:noise. Cell lines were incubated with EdU for 2 hours and primary cells for 4 hours.  156 
 157 
Immunohistochemistry 158 
A formalin-fixed paraffin embedded cholangiocarcinoma tissue microarray (TMA) was 159 
purchased from Abcam (ab178201). Antigen retrieval was performed using 10 mM citrate, 160 
0.05% tween-20, pH 6.0 in a microwave on full power (800 W) for 30 minutes. The array 161 
was stained using an in-house polyclonal mouse anti-PRH antibody and the Vector 162 
ImmPRESS kit (Vector labs, MP-7402), and imaged on a Zeiss Axio Scan.Z1 microscope. 163 
 164 
Immunocytochemistry 165 
Cells were seeded onto poly-L-lysine-coated glass coverslips and left to adhere for 24 hours. 166 
Cells were washed with PBS and fixed using 4% formaldehyde in PBS for 10 minutes. Cells 167 
were permeabilized using 0.1% Triton X-100 in PBS for 10 minutes then blocked in 5% BSA 168 
+ 20% serum from the secondary antibody host species in PBS. Primary antibodies used were 169 
E-cadherin (Cell Signaling Technology, 24E10) and β-catenin (Cell Signaling Technology, 170 
D10A8). Secondary antibody was Texas Red conjugated anti-rabbit IgG (Sigma-Aldrich, 171 
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SAB3700873). Cells were mounted using Prolong Gold with DAPI (ThermoFisher, P36931), 172 
and imaged using a Zeiss LSM 780 confocal microscope. 173 
 174 
Western blotting 175 
The following primary antibodies were used for Western blotting: PRH (in-house mouse 176 
polyclonal (33)), E-cadherin (Cell Signaling Technology, 24E10), Lamin A/C (Santa Cruz, 177 
H-110), myc tag (Cell Signaling Technology, 9B11), Notch3 (Cell Signaling Technology, 178 
D11B8), Vimentin (Cell Signaling Technology, D21H3), Cyclin D2 (Cell Signaling 179 
Technology, D52F9), Rb (Cell signalling Technology, 4H1), Phospho-Rb (Ser807/811) (Cell 180 
signalling Technology, 9308). 181 
 182 
Quantitative RT-PCR 183 
RNA was extracted using a Bioline Isolate II kit according to the manufacturer’s instructions. 184 
1μg of total RNA was used for reverse transcription (Quantitect Reverse Transcription kit 185 
(Qiagen, 205311)). qRT-PCR was performed in a Rotor-Gene Q cycler (Qiagen) using 186 
Quantitect SYBR green PCR kit (Qiagen, 204143). Genes of interest were normalised to β-187 
actin expression using primer efficiency normalised relative quantification, with primer 188 
efficiencies calculated from standard curves generated from cDNA dilutions. All primers are 189 
listed in supplementary table 1. 190 
 191 
Mouse xenografts 192 
All animal experiments and procedures were approved by the UK Home Office in accordance 193 
with the Animals (Scientific Procedures) Act 1986, and the Guide for the Care and Use of 194 
Laboratory Animals was followed. 10
6
 CCLP-1 PRH knockdown or scrambled control cells 195 
were resuspended in 100 μL Matrigel and injected subcutaneously into the flank of male CD-196 
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1 nude mice. Tumours were measured with a calliper every three days until the 197 
tumour reached 12 mm in diameter. Tumour volume was estimated using the following 198 
formula: [(length+width)/2]*length*width.  199 
 200 
RNA sequencing 201 
RNA was isolated using a Bioline Isolate II kit according to the manufacturer’s instructions. 202 
Total poly-adenylated RNA was purified and adapter ligated using Illumina TruSeq RNA 203 
Library Prep kit according to the manufacturer’s instructions. This was followed by Illumina 204 
sequencing of 75bp paired end reads (minimum 2x35 million reads/sample). Each 205 
experimental condition was run in biological duplicate. Reads were quality-trimmed using 206 
TrimGalore!, aligned using the gapped read mapper TopHat and differential expression 207 
analysis was performed using DESeq2. Gene Ontology analysis was performed using the 208 
PANTHER webserver (http://www.pantherdb.org) and Gene Set Enrichment Analysis for 209 
Hallmark gene sets was performed using the Broad Institute GSEA webserver 210 
(http://software.broadinstitute.org/gsea/msigdb). Raw and processed RNA-seq data has been 211 
submitted to NCBI GEO database Accession no. GSE124429.  212 
 213 
ChIP sequencing 214 
CCLP1 cells were infected with a recombinant adenovirus to express myc-PRH. Chromatin 215 
immunoprecipitation of myc-PRH (using the same antibody as for myc-tag Western blots) 216 
was carried out as previously described (34) with 1.5×10
7
 CCLP1 cells infected with Ad-217 
myc-PRH or empty adenovirus at MOI 50 for 48hrs. Sequencing libraries were prepared 218 
using NEBNext Ultra II DNA Library preparation kit, followed by Illumina sequencing of 219 
100bp reads (minimum 20 million reads/sample). Reads were quality-trimmed using 220 
TrimGalore!, aligned using Bowtie2 and peaks were called using MACS2. Chromatin 221 
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prepared from empty adenovirus infected cells and subjected to myc tag immunoprecipitation 222 
was used as background in sequencing and peak calling. De novo motif analysis of ChIP 223 
peaks was performed using HOMER. Raw and processed ChIP-seq data has been submitted 224 
to NCBI GEO database Accession no. GSE124430.  225 
 226 
TCF/LEF reporters 227 
TCF/LEF dependent transcriptional activity was measured using the TOPflash firefly 228 
luciferase reporter system, in which the firefly luciferase gene is downstream of several 229 
TCF/LEF consensus binding sites; the same construct with scrambled TCF/LEF sites 230 
(FOPflash) is used to determine the TCF/LEF-independent activity of the promoter. Firefly 231 
luciferase activity was normalised to Renilla luciferase activity from a constitutively active 232 
promoter (pRL, Promega, E2261). For over-expression experiments, reporter constructs were 233 
co-transfected with either myc-PRH, myc-PRH N187A DNA-binding deficient mutant (32) 234 
or 3xFLAG-Notch3-ICD (hNICD3(3xFLAG)-pCDF1-MCS2-EF1-copGFP, a gift from 235 
Brenda Lilly, Addgene plasmid #40640) expression vectors.  236 
 237 
Soft agar colony formation 238 
Colony formation assays and subsequent imaging were done as described by Borowicz et al 239 
(35). 10
3
 cells were plated per well and colonies were imaged after 10 days. 240 
 241 
Transwell migration 242 
Cells were starved overnight in serum-free medium with 0.2% BSA and 1mM hydroxyurea. 243 
24 well ThinCert
 
inserts (Greiner bio-one) were placed in the wells of a 24 well plate. 600μL 244 
DMEM with 10% serum was added to each. 200 μL of serum-free medium with 0.2% BSA 245 
containing 2x10
5
 cells was added to each insert. After 72 hours medium was replaced with 246 
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450 μL of 8 μM calcein-AM in DMEM with 10% serum. After 45 minutes incubation, inserts 247 
were transferred to a fresh 24 well plate containing 500 μL prewarmed Trypsin-EDTA in 248 
each well. 200 μL of the Trypsin-EDTA cell suspension was transferred to a black flat 249 
bottom 96 well plate. The fluorescence signal was read in a fluorescence plate reader at an 250 
excitation wavelength of 485 nm and an emission wavelength of 520 nm.  251 
 252 
Matrigel invasion 253 
For invasion assays, insert transwells with 8.0 μm polycarbonate membrane (Corning costar, 254 
New York, NY, USA) were coated with 50 μl of a 1:10 mixture of Matrigel™ 255 
(BDBiosciences, San Jose, CA, USA) in serum free medium. Cells were infected with Ad-256 
empty or Ad-PRH (moi 50) and 24 hours after infection cells incubated with 1mM 257 
hydroxyurea. 48 hours after infection 10
4
 cells were plated per well in serum free media 258 
containing 1mM hydroxyurea (200ul) and left to invade towards complete medium (500ul) in 259 
the bottom chamber for 24 hours. Cells remaining on underside of insert after swabbing with 260 
a cotton swab were fixed in methanol for 5 mins and stained with 0.1%w/v crystal violet in 261 
12% glutaraldehyde in water for 5 mins and counted by microscopy.  262 
 263 
 264 
  265 
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PRH is highly expressed in CCA.  267 
Analysis of the cholangiocarcinoma dataset (n=45) in The Cancer Genome Atlas (TCGA) 268 
revealed elevated expression of PRH mRNA in CCA samples compared to all TCGA 269 
samples, with a mean log2 fold-change of 3.2±0.9 (Fig.S1A) and high PRH expression is 270 
limited to a small number of tumour types (Fig.S1B). In the majority of CCA samples, 271 
elevated PRH mRNA expression is in the absence of gene amplification and in several 272 
samples the transcript is elevated despite a single allele deletion. No coding mutations in the 273 
HHEX gene encoding PRH were detected in any CCA samples. To examine PRH protein 274 
staining intensity in CCA samples we performed immunohistochemistry on a tissue 275 
microarray containing 2 tumour cores and a non-involved border core from 42 CCA patients 276 
(Abcam). Representative immunohistochemistry images of carcinomas and patient-matched 277 
border bile ducts are shown in Fig.1A. Of the 42 non-involved border cores, 26 had at least 278 
one bile duct. In a paired analysis of these 26 samples compared to their matched carcinoma, 279 
we found increased PRH staining intensity in 20/26 (p=0.00005), and in an unpaired analysis 280 
comparing all 42 carcinomas to the 26 non-involved bile ducts we found a 20% increase in 281 
median PRH expression (p=0.0004, Fig.1B). We did not find any differences in PRH staining 282 
intensity between different grades or TNM stages of carcinoma, although this may reflect 283 
lack of statistical power as the majority of our samples were from grade II tumours.  We next 284 
examined PRH protein expression in four CCA cell lines compared to immortalised AKN-1 285 
biliary epithelial cells (BECs) and two independently isolated primary human BEC cultures 286 
derived from livers with alcoholic liver disease (ALD) and steatotic liver disease (NASH). 287 
All four CCA cell lines showed increased PRH protein expression (Fig.1C) and we conclude 288 
that PRH mRNA and protein is highly expressed in CCA compared to primary BECs.  289 
  290 
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PRH promotes tumour growth by CCLP1 cells in nude mice. 291 
To determine whether elevated PRH is important in CCA we generated stable PRH 292 
knockdown (KD) in CCLP1 CCA cells. Western blotting and quantitative RT-PCR 293 
demonstrated effective knockdown of PRH (Fig.S1C and S1D). One million CCLP1 control 294 
and PRH knockdown cells were then injected subcutaneously into nude mice and tumour size 295 
measured over 25 days and at the termination of the experiment. Only 3/9 mice injected with 296 
PRH knockdown cells produced tumours compared to 9/9 controls (p=0.003) and knockdown 297 
of PRH expression significantly reduced tumour growth (Fig.1D). PRH knockdown also 298 
reduced the proportion of CCLP1 cells able to form colonies in soft agar (Fig.1E) and the 299 
average colony cross-sectional area (Fig.1F). To test whether over-expression of PRH in 300 
BECs would be sufficient to recapitulate the phenotype observed in CCLP1 cells, AKN1 301 
immortalised BECs were transfected with a double-tagged GFP-PRH-myc expression vector 302 
and selected to generate a stable GFP-PRH-myc expressing cell line. In addition we over-303 
expressed PRH in primary BECs using an adenovirus expressing myc-tagged PRH. Colony 304 
formation in soft agar was increased in an AKN1 cell population over-expressing PRH 305 
compared to controls (Fig.1G-H) and strikingly, when expressing myc-PRH multiple 306 
independently isolated primary BEC populations from different donors were able to form 307 
colonies in soft agar whereas controls were not (Fig.1I). We conclude that elevated PRH 308 
expression promotes anchorage-independent growth of primary and immortalised BECs in 309 
vitro and that reduction of PRH levels inhibits CCLP1 tumour growth in a xenograft model. 310 
 311 
PRH drives CCA cell proliferation.  312 
To examine why depletion of PRH in CCA cells decreases tumour growth in nude mice we 313 
examined the effect of PRH depletion and PRH over-expression on cell proliferation in 314 
culture. Knockdown of PRH in CCLP1 cells reduced cell growth, with the doubling time 315 
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increasing from 28±3 to 40±4 hours (Fig.S1E). To determine whether this was due to reduced 316 
proliferation or increased cell death we measured proliferation by EdU incorporation and 317 
apoptosis by caspase-3 enzymatic activity assay. EdU incorporation was reduced to 53±7% 318 
of control with PRH shRNA knockdown (Fig.2A). There was a small decrease in caspase-3 319 
activity in PRH knockdown cells compared to controls (Fig.S1F). We conclude that the 320 
reduction in cell number on PRH knockdown was predominantly a result of decreased cell 321 
proliferation. To determine whether this was a CCLP1-specific effect, or an off target effect 322 
of the PRH shRNA, we also measured EdU incorporation in KKU-M055 and KKU-M213 323 
CCA cells 72 hours after transfection with a PRH siRNA with a different target sequence to 324 
the shRNA. EdU incorporation was reduced in both cell types (Fig.S1G) ruling out cell line-325 
specific effects and off-target effects of the shRNA. To confirm that PRH promotes the 326 
proliferation of CCA cells we over-expressed PRH in CCLP1 and CCSW1 CCA cells using a 327 
recombinant adenovirus encoding myc-PRH (Fig.S2A). Over-expression of myc-PRH in both 328 
cell lines increased EdU incorporation (Fig.2B) and increased growth rate, with doubling 329 
times decreased from 30±3 to 22±1 hours and 29±4 to 19±3 hours, respectively (Fig.S2B). 330 
Caspase-3 activity was also robustly decreased (Fig.S2C). Proliferation measured by EdU 331 
incorporation was increased by PRH over-expression in both primary BECs and AKN1 cells 332 
(Fig.2C). We conclude that PRH over-expression promotes the proliferation of primary BECs 333 
and CCA cell lines and reduces basal levels of apoptosis. 334 
 335 
PRH maintains the mesenchymal phenotype of CCA cells.  336 
Following PRH knockdown in culture we noticed a marked change in morphology of CCLP1 337 
cells from an elongated mesenchymal-like morphology to an epithelial-like morphology 338 
(Fig.2D). Unlike normal BECs, CCLP1 cells do not express the epithelial cell adhesion 339 
molecule E-cadherin. However, E-cadherin expression was restored upon PRH knockdown 340 
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(Fig.2E) and the mesenchymal marker protein Vimentin was also strongly decreased  in these 341 
cells (Fig.2E, lower). As changes in cell morphology and E-Cadherin expression are 342 
associated with mesenchymal to epithelial transition (MET) we measured the migration and 343 
invasion of PRH depleted CCLP1 cells in response to a serum gradient. Proliferation was 344 
inhibited by hydroxyurea treatment in both experiments. PRH knockdown reduced the 345 
number of migrated cells (Fig.2F) and reduced the number of invaded cells (Fig.2G). 346 
Overexpression of PRH in the presence of hydroxyurea increased the invasion of both 347 
CCLP1 and CCSW tumour cell lines (Fig.S2D). Over-expression of PRH in both AKN1 and 348 
primary human BECs reduced E-Cadherin expression and increased expression of Vimentin 349 
(Fig.2H). In addition, PRH over-expression increased cell migration and matrix invasion by 350 
both primary BECs and AKN1 cells (Fig.2I-J). As might be expected based on these results, 351 
PRH expression in AKN1 cells resulted in a change from an epithelial-like cell morphology 352 
to a more mesenchymal cell morphology (Fig.2K). We therefore examined changes in the 353 
expression of EMT-related genes in AKN1 cells over-expressing PRH using qRT-PCR. The 354 
epithelial and mesenchymal marker genes CDH1 and VIM encoding E-Cadherin and 355 
Vimentin were down-regulated and upregulated respectively, following PRH expression 356 
(Fig.S2E). In addition, the genes encoding EMT transcription factors (ZEB1, TWIST1) were 357 
upregulated in AKN1 cells expressing PRH. Thus PRH over-expression in primary BECs and 358 
in an immortalised BEC cell lines supresses the epithelial phenotype and promotes a 359 
migratory mesenchymal phenotype. 360 
 361 
PRH regulates pathways associated with Wnt signalling and with EMT.  362 
To understand how PRH promotes the proliferation of CCA cells and maintains a 363 
mesenchymal phenotype, we performed RNA sequencing (RNA-seq) with total poly-364 
adenylated RNA isolated from CCLP1 cells with stably knocked down or transiently over-365 
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expressed PRH. We found 189 down-regulated and 430 up-regulated genes in PRH 366 
knockdown cells, and 889 down-regulated and 1410 up-regulated genes in PRH over-367 
expressing cells when compared to their respective controls (Fig.3A). To validate the RNA-368 
seq data, we performed qRT-PCR for several genes identified as differentially expressed, all 369 
of which were in agreement with the RNA-seq (Fig.S3A). Gene Set Enrichment Analysis 370 
(GSEA) using the Molecular Signatures Database (MSigDB) Hallmark gene sets (36) showed 371 
that both PRH knockdown and PRH over-expression led to the differential expression of 372 
genes within the same pathways many of which have been shown to be aberrantly activated 373 
in CCA including EMT, Wnt/β-catenin, TGF-β, IL6/JAK/STAT3 and estrogen signalling 374 
(Fig.3B and Fig.3C). Gene Ontology (GO) term enrichment analysis was in broad agreement 375 
with GSEA analysis and suggested enrichment of genes associated with epithelial and 376 
mesenchymal differentiation as well as genes associated with both canonical and non-377 
canonical Wnt signalling (Fig.S3B and S3C). We also noted changes in the expression of 378 
multiple transcription factors and markers associated with biliary differentiation and Notch 379 
signalling (Fig.3D). These results are suggestive of alteration of the transcriptional network 380 
underlying biliary differentiation upon PRH knockdown. 381 
In addition, GO analysis identified enrichment of genes associated with the control of cell 382 
proliferation in both the knockdown and over-expression experiments, including genes 383 
encoding cyclin D2 (CCND2), and the p27 (CDKN1B) and p15 (CDKN2B) cyclin-dependent 384 
kinase (CDK) inhibitors (Fig.S3B and Fig.S3C), and GSEA analysis showed enrichment of 385 
the G2M gene set which contains cell cycle genes (Fig.S3C). Of particular interest in the 386 
GSEA data was the finding that Notch and PI3K/Akt pathway genes were enriched in the 387 
PRH over-expression gene set (Fig.3C) as NOTCH3 oncogenic activity in CCA models is at 388 
least partly due to non-canonical NOTCH signalling via PI3K/Akt (10). Furthermore, the 389 
NOTCH3 gene was one of the 53 genes that were differentially regulated in both PRH over-390 
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expression and knockdown data sets, and both qRT-PCR and Western blotting showed 391 
reduced NOTCH3 gene expression and Notch3 ICD protein expression in PRH knockdown 392 
cells (Fig.3D and 4A, respectively).   393 
A PRH-Notch3 positive feedback loop promotes cell proliferation and EMT.   394 
To determine whether NOTCH3 expression was increased by PRH in other CCA cell lines 395 
we over-expressed myc-PRH and a DNA binding deficient myc-PRH N187A mutant in 396 
CCLP1 and CCSW1 cells. Wild-type PRH but not the DNA binding deficient mutant 397 
increased NOTCH3 mRNA (Fig.4B) and protein levels in these cells (Fig.4C). Furthermore, 398 
we found a striking correlation between PRH expression and Notch3 expression in cell lines 399 
and primary BECs (Fig.4D). In addition, HHEX and NOTCH3 gene expression positively 400 
correlated in the TCGA CCA RNA-seq dataset as do HHEX and HES1 gene expression 401 
(Fig.S3D and S3E), suggesting that PRH regulates NOTCH3 and HES1 in primary tumours. 402 
Finally, over-expression of PRH in both primary BECs and AKN1 cells led to expression of 403 
the Notch3 protein (Fig.4E). 404 
To determine whether the effects of PRH knockdown are recapitulated by depletion of 405 
Notch3, we generated Notch3 knockdown CCLP1 cells by integrating a Notch3 shRNA 406 
plasmid (Fig.4F). Strikingly, the proliferative and morphological phenotype of PRH 407 
knockdown cells (Fig.2A and 2D) was reproduced by Notch3 knockdown (Fig.4F-H). 408 
Moreover, knockdown of Notch3 resulted in a reduction of HHEX mRNA (Fig.S3F) and 409 
PRH protein (Fig.4F). These data suggest that PRH and Notch3 could form a positive 410 
transcriptional feedback loop where each regulates the other.  411 
To better understand the transcriptome changes underlying the common phenotype between 412 
Notch3 and PRH knockdown cell lines, we performed RNA-seq with Notch3 knockdown and 413 
scrambled shRNA cell lines and compared differentially expressed genes (DEGs) in PRH 414 
knockdown cells to those in Notch3 knockdown cells. These experiments clearly showed that 415 
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both factors act in the same pathways as the DEGs after PRH depletion were a subset of those 416 
differentially expressed after Notch3 knockdown (see Venn diagrams, Fig.4I). In agreement 417 
with this finding, the gene sets enriched in the Notch3 knockdown DEGs were largely the 418 
same sets enriched in PRH knockdown (red bars, Fig.4J), with a small number of Notch3-419 
specific sets (black bars) including PI3K/Akt signalling and Notch signalling. In agreement 420 
with the GSEA, Western blotting experiments showed that both PRH knockdown and Notch3 421 
knockdown reduced phosphorylation of Akt at both T308 and S473 (both of which are known 422 
to increase kinase activity, T308 by 100-fold and S473 by a further 10-fold for full kinase 423 
activity (37)) (Fig.S3G).  424 
 425 
Notch3-dependent and Notch3-independent PRH target genes.  426 
To separate PRH-regulated genes into Notch3-dependent (Notch correlated) and Notch3-427 
independent (PRH correlated) subgroups, we over-expressed PRH in Notch3 knockdown 428 
CCLP1 cells. Figure 5A shows qRT-PCR analyses examining representative PRH-correlated 429 
and Notch3-correlated genes. Expression of the PRH regulated EMT associated genes CDH1 430 
and VIM, as well as CCND2 was regulated by Notch3 rather than by PRH alone and this 431 
result was reproduced at protein level (Fig.5B). EdU incorporation experiments after over-432 
expression of PRH in Notch3 knockdown cells suggested that PRH was unable to drive 433 
proliferation when it was decoupled from activation of Notch3 expression (Fig.5C). 434 
Interestingly, we noted a reduced level of PRH mRNA and protein expression from the 435 
adenoviral PRH construct in the Notch3 knockdown cells compared to the control (Fig.5A 436 
and Fig.5B) suggesting that Notch3 may regulate PRH expression at the level of transcript 437 
stability. We found the same effects on proliferation and expression of genes and proteins 438 
shown in Fig.5A/B when the viral MOI was increased in the Notch3 knockdown cells to give 439 
equal PRH protein expression and we therefore proceeded to perform RNA-seq in the 440 
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presence of equal MOIs. Across all four sample combinations, we found 5397 DEGs which 441 
were correlated with either PRH or Notch3 expression. Of these, 4356 were Notch3-442 
correlated (2110 positively correlated i.e. activated downstream of Notch3, and 2246 443 
negatively correlated i.e. repressed downstream of Notch3), and 1041 were PRH-correlated 444 
(604 positively and 437 negatively)(Fig.5D). We found strong enrichment of c-myc target 445 
genes when we performed GSEA analysis on the 1041 PRH correlated genes (Fig.5D lower 446 
panel). In addition to c-myc target genes, we found enrichment of a variety of gene sets 447 
(including Wnt/β-catenin signalling) that are also enriched in the Notch3-correlated gene set, 448 
suggesting that PRH and Notch3 regulate different genes in the same pathways (Fig.5D). 449 
Finally, we present summary heat maps with hierarchical clustering analysis of all RNA-seq 450 
samples showing PRH dependence, Notch dependence or co-dependence of genes (Fig.S4A) 451 
and heat maps with hierarchical clustering analysis of RNA-seq samples for selected 452 
pathways (Fig.S4B).   453 
 454 
Identification of PRH binding sites in CCA cells.  455 
To identify putative direct targets of PRH, we determined the genome-wide binding sites of 456 
PRH in CCLP1 cells using chromatin immunoprecipitation sequencing (ChIP-seq) with a 457 
myc-tag antibody and chromatin prepared from myc-PRH or empty adenovirus infected 458 
CCLP1 cells and assigned ChIP peaks to the nearest transcription start site within 100kb. 459 
Comparison of these putative direct PRH target genes with the DEGs from the myc-PRH 460 
over-expression RNA-seq experiment suggests that of the 1410 up-regulated genes, only 143 461 
(10.1%) were direct targets, whereas of the 889 down-regulated genes, 397 (44.7%) were 462 
direct PRH targets (see Venn diagram, Fig.5E). These data produced the first consensus 463 
binding site identified for PRH in cells (Fig.5F); the most strongly enriched motif (64.2% of 464 
peaks, p=10
-96
) underlying PRH ChIP-seq peaks contains a core ATTA motif characteristic of 465 
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homeodomain transcription factor binding sites (Fig.5F) and is in good agreement with the 466 
avian PRH binding site determined in vitro by SELEX (38). Variants of this sequence have 467 
been identified upstream of several PRH regulated genes in other cell types (39). Analysis of 468 
the putative directly regulated genes using GSEA, revealed enrichment of genes associated 469 
with apoptosis, proliferation (mitotic spindle and G2M checkpoint), EMT, and signalling 470 
pathways including IL6, IL2, p53 and TNF-α (Fig.S5A). Multiple genes associated with 471 
EMT including genes involved in cell adhesion or cell migration were present in these 472 
groups, however these targets do not include the SNAI/TWIST/ZEB families of EMT 473 
transcription factors that regulate CDH1 or CDH1 itself. PRH did not directly bind near 474 
NOTCH3 and thus PRH may regulate Notch pathway genes by indirect means. However, 475 
CDKN1B and CDKN2B genes (Fig.S5B and Fig.S5C) and a number of genes associated with 476 
Wnt signalling including DKK1, WNT11 (Fig.5G and Fig.5H), TCF7L1 and WNT16 had 477 
nearby PRH ChIP peaks.  478 
 479 
Notch3-dependent and Notch3-independent effects on Wnt signalling.   480 
To determine whether PRH regulates Wnt signalling in these cells, we made use of the 481 
TOPFlash TCF/LEF luciferase Wnt-signalling reporter system (40). Transient transfection of 482 
plasmids encoding myc-PRH into both CCLP1 and CCSW1 cells significantly increased 483 
TOPFlash activity compared to the empty vector control (Fig.6A) or after over-expression of 484 
the DNA-binding deficient N187A PRH mutant (Fig.6A, inset). Transfection of FLAG-485 
Notch3-ICD did not alter the activity of the TOPFlash reporter (Fig.6A) despite robust 486 
protein expression (Fig.S3H) and changes in the expression of Notch3 target genes (HEY2 487 
and CCND2, Fig.S3I). This suggests that genes directly downstream of PRH rather than 488 
genes regulated by Notch3 are crucial for controlling the output of the canonical Wnt 489 
signalling pathway in these cells.  490 
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β-catenin facilitates cross-talk between canonical Wnt signalling and cell-cell adhesion by 491 
acting as a co-activator for TCF/LEF transcription factors and a structural component of the 492 
adherens junctions complex that includes E-cadherin (41). Although there was no change of 493 
β-catenin gene expression after PRH over-expression or knockdown, we observed a large 494 
increase in E-cadherin expression after PRH knockdown in CCLP1 cells (Fig.2E) and 495 
decreased E-cadherin expression after PRH over-expression in BECs (Fig.2H). PRH 496 
knockdown reduced β-catenin nuclear localization compared to the control as measured by 497 
immunofluorescence micrographs (Fig.6B) and densitometry of Western blots for β-catenin 498 
following subcellular fractionation (Fig.6C). TCF/LEF reporter activity in PRH knockdown 499 
CCLP1 cells was also decreased (Fig.6D). To determine whether the increased expression of 500 
E-cadherin could explain the reduction in TCF/LEF transcriptional activity in PRH KD cells, 501 
we restored E-cadherin protein expression independently of EMT transcription factors in 502 
CCLP1 cells by generating a stable cell line expressing the CDH1 gene under the control of 503 
the CMV promoter. Expression of E-cadherin decreased TOPFlash reporter activity (CDH1 504 
empty TOP compared to pcDNA empty TOP in Fig.6E), suggesting that the increase in E-505 
cadherin seen on PRH depletion (and consequent decrease in -catenin nuclear localisation) 506 
is likely to be responsible for decreased Wnt signalling. Moreover, E-cadherin over-507 
expression significantly reduced the ability of PRH to increase TOPFlash reporter activity 508 
(Fig.6E). Taken together, these data indicate that PRH directly promotes aberrant expression 509 
of Wnt pathway genes leading to activation of Wnt-responsive transcription independently of 510 
Notch3. In addition, repression of CDH1 downstream of PRH via Notch3 amplifies the 511 
aberrant PRH-dependent Wnt signal. Thus PRH and Notch3 exert regulation over Wnt 512 
signalling at multiple levels. 513 
 514 
PRH over-expression and sensitivity to chemotherapeutic drugs.  515 
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As PRH regulated several components of the Notch signalling pathway including γ-secretase 516 
components, we investigated whether PRH could modulate the inhibition of cell proliferation 517 
by γ-secretase inhibition. Treatment with the γ-secretase inhibitor DAPT had a greater 518 
inhibitory effect on the proliferation of CCLP1 cells than it did on the proliferation of CCLP1 519 
cells over-expressing PRH (Fig.7A). To summarise these data we calculated a log ratio of 520 
sensitivity between CCLP1 and PRH over-expressing CCLP1, as 521 
log2((PPRH,drug/PPRH,vehicle)/(Pempty,drug/Pempty,vehicle)) where P is the relative proliferative rate 522 
measured by EdU incorporation (Fig.7B). The log ratio is negative if PRH expression 523 
increases sensitivity to a drug, and positive if it increases resistance.  PRH also drives 524 
canonical Wnt signalling in CCA cell lines, and we wondered whether the anti-proliferative 525 
effect of Wnt pathway inhibition previously reported in CCA cell lines (7) would be 526 
modulated by the PRH expression level. Treatment with the β-catenin/CBP interaction 527 
inhibitor ICG-001 had a greater inhibitory effect on the proliferation of CCLP1 cells than it 528 
did on the proliferation CCLP1 cells over-expressing PRH (Fig.7A/7B and dose-response 529 
curve Fig.S6A). These data indicate that high PRH levels induce resistance to canonical Wnt 530 
pathway inhibition by ICG-001 as well as resistance to γ-secretase inhibition. It has recently 531 
been shown in a mouse model of AML that repression of Cdkn2a by PRH is dependent on 532 
recruitment of Polycomb repressive complex 2 (PRC2) (23). We therefore tested whether 533 
inhibition of EZH2, the catalytic subunit of PRC2 (using UNC1999), would block 534 
proliferation of CCLP1 cells in a PRH-dependent fashion. However, although EZH2 535 
inhibition reduced cell proliferation, the effect was PRH-independent (Fig.7A/7B).  536 
Since exogenous PRH represses CDKN1B and CDKN2B and activates CCND2 indirectly via 537 
Notch3 we next examined whether inhibition of CDK4/6 using palbociclib would block 538 
proliferation in CCLP1 cells and whether sensitivity to this drug is modulated by PRH 539 
expression level. EdU incorporation experiments with CCLP1 cells over-expressing PRH in 540 
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the presence of palbociclib showed that high levels of PRH sensitised CCLP1 cells to the 541 
anti-proliferative effects of palbociclib (Fig.7A/7B and dose-response curve Fig.S6B). We 542 
conclude that PRH over-expression drives CDK4/6 activity via both increased expression of 543 
cyclin D2 (via Notch3) and by direct repression of p15 and p27 expression. To determine 544 
whether increased PRH levels result in increased sensitivity to palbociclib in other CCA cell 545 
lines, we over-expressed the protein in a panel of cell lines in the presence of palbociclib and 546 
measured EdU incorporation. Figure 7C shows the log ratio of sensitivity between control 547 
cells and PRH over-expressing cells in each case. In all of the cell lines tested increased PRH 548 
levels result in increased sensitivity to palbociclib treatment.  549 
The effect of palbociclib on cell proliferation is thought to be dependent on the presence and 550 
inhibition of phosphorylation of the Rb tumour suppressor protein (42). We therefore 551 
examined Rb expression in the CCA cell lines and BECs used in this study.  Interestingly, Rb 552 
protein expression was very low or not detectable in primary BECs or immortalised BECs 553 
although it is present in CCA cell lines (Fig.S7A). Moreover, treatment of CCA cell lines 554 
with palbociclib at their LD50 reduced the levels of phosphorylated Rb in each case 555 
(Fig.S7B). To determine whether the effects of palbociclib on the proliferation of CCLP1 556 
cells requires the presence of Rb we knocked down Rb using siRNA. Although the 557 
proliferation of control cells was inhibited by palbociclib treatment, Rb knockdown CCLP1 558 
cells are far less sensitive to the effects of this drug (Fig.7D).  In addition, palbociclib has no 559 
effect on the proliferation of PRH knockdown CCLP1 cells (Fig.7D). 560 
Figure 7E summarises the transcriptome and phenotypic changes that are dependent on PRH 561 
expression and the associated altered sensitivities to palbociclib and other chemotherapeutics. 562 
We conclude that the clinical efficacy of various chemotherapeutic strategies is likely to 563 
depend on PRH expression level, and that patient stratification on the basis of PRH 564 
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expression could improve the clinical usefulness of several compounds that have recently 565 
been suggested as potential novel CCA treatments including palbociclib. 566 
  567 
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Previous work in a variety of animal and in vitro models has suggested that hyper-activation 570 
of both Wnt signalling (7) and Notch signalling (10) are crucial events in carcinogenesis and 571 
progression of CCA. Here we show that both of these events have a common origin in the 572 
dysregulation of PRH. We reveal that the PRH protein is elevated in human CCA cell lines 573 
and primary tumours relative to primary BECs and we use a xenograft model and colony 574 
formation assays with primary human biliary epithelial cells to demonstrate the importance of 575 
PRH in CCA. We show that PRH depletion in CCA cells decreases cell proliferation and 576 
inhibits cell migration and cell invasion and brings about changes in gene expression 577 
consistent with MET. The ability of PRH to influence tumour cell behaviour is not confined 578 
to increasing cell proliferation and maintaining a mesenchymal phenotype in CCA cell lines. 579 
Indeed over-expression of PRH increases cell proliferation, migration, invasion and 580 
anchorage independent growth of primary human BECs and AKN1 cells. Moreover transient 581 
elevated PRH expression in primary BECs induces changes in gene expression characteristic 582 
of EMT. Collectively these experiments show that PRH is a novel oncoprotein in at least a 583 
large proportion of CCA tumours and they suggest that PRH dysregulation underlies both 584 
CCA and the biliary pathologies that precede CCA.   585 
 586 
PRH regulates NOTCH3 in CCA 587 
We have shown that PRH is a regulator of NOTCH3 gene expression. However, ChIP-seq 588 
experiments did not show binding of PRH near NOTCH3 or near to any of the other PRH-589 
regulated genes in the Notch pathway, such as NOTCH1, JAG1 and JAG2. Although the 590 
regulation of NOTCH3 appears to be indirect, it is one of only 53 genes that are differentially 591 
expressed upon both over-expression and knockdown of PRH. We also show that NOTCH3 592 
knockdown decreases PRH expression and that this creates a positive feedback loop.  One 593 
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consequence of activation of a Notch3-PRH positive reinforcement loop in CCA and in 594 
primary BECs is that a small perturbation to the activity or expression of either factor could 595 
lead to amplification of gene expression changes that ultimately give rise to the phenotypic 596 
alterations associated with CCA. Since we observed a strong correlation between HHEX and 597 
NOTCH3 gene expression in the whole TCGA dataset, which contains samples with a variety 598 
of driver mutations, we propose that a positive feedback loop between Notch3 and PRH is 599 
initiated independently of the underlying mutational landscape through common changes in 600 
the tumour microenvironment and the intracellular signalling milieu. We also see correlation 601 
of HHEX and HES1mRNA expression which may occur because of co-regulation of HES1 by 602 
PRH and Notch3. The co-activation of multiple genes in the pathway such as the gamma 603 
secretase activator PSEN2 by Notch3 and PRH likely also leads to the increase in Notch3 604 
ICD observed following PRH expression. 605 
Previous studies showed that Notch3 promotes PI3K/Akt signalling in CCLP1 cells in a non-606 
canonical manner (10). Here we present the first genome-wide identification of Notch3 607 
regulated genes in CCA and we use GSEA to show that multiple PI3K/Akt/mTOR pathway 608 
genes are regulated by Notch3.  Interestingly, the most strongly enriched pathway in the 609 
Notch3-correlated gene set is ‘cholesterol homeostasis’, and ‘bile acid metabolism’ is also 610 
enriched. Cholesterol-derived conjugated bile acids can drive cholangiocarcinoma cell 611 
proliferation and cholestasis is a known risk factor for CCA (43, 44) suggesting that part of 612 
the effect of Notch3 in CCA could be due to dysregulation of bile acid synthesis and 613 
metabolism.  614 
 615 
PRH regulates Wnt signalling  616 
PRH over-expression in CCLP1 cells resulted in the differential expression of several genes 617 
involved in Wnt signalling including WNT11, WNT16, TCF7L1 and the endogenous LRP6 618 
Research. 
on January 8, 2020. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 16, 2019; DOI: 10.1158/0008-5472.CAN-19-0942 
28 
 
inhibitor DKK1, and PRH ChIP-seq showed binding of PRH at these loci. These results 619 
suggest that PRH directly regulates several key genes in the Wnt signalling pathway. PRH 620 
also indirectly promotes Wnt signalling in CCLP1 cells through Notch3-mediated repression 621 
of CDH1. We infer that the dominant effect of Notch3 on Wnt signalling is to increase the 622 
available pool of catenin and thus amplify the effects of PRH on Wnt signalling. In 623 
addition our PRH over-expression ChIP-seq and RNA-seq data reveal that many EMT-624 
associated genes are direct targets of PRH, including FAP, DST and ITGAV. Thus we 625 
conclude that PRH and Notch3 collaborate to drive EMT and Wnt signalling; PRH directly 626 
regulates genes that impact on both pathways and indirectly regulates additional genes in the 627 
same pathways via Notch3. Macrophages in the tumour microenvironment have been 628 
proposed to provide a source of Wnt ligands to drive the dysregulated Wnt signalling 629 
observed in CCA (7). We suggest that independently of exogenous Wnts, the Notch3-PRH 630 
loop may also drive aberrant autocrine Wnt signalling in CCA.  631 
PRH plays a complex role in liver development; PRH null mice are embryonic lethal (45) 632 
with multiple defects including defective liver development, decreased proliferation and 633 
migration of hepatic progenitors (46, 47). Conditional deletion of PRH (FoxA3-Cre) results 634 
in liver hypoplasia and loss of extrahepatic ducts, whereas a later conditional deletion (Alfp-635 
Cre) results in viable mice with cystic ducts and decreased differentiated intrahepatic bile 636 
ducts (48).  Here we show that PRH protein expression is turned off in mature human bile 637 
ducts and that its re-expression in bile duct epithelial cells promotes cell proliferation and cell 638 
invasion.  One possibility is that the aberrant expression of PRH in differentiated adult bile 639 
duct cells mimics the role that PRH plays in promoting tissue growth in early organogenesis 640 
as the PRH partners that are required for PRH dependent bile duct differentiation are likely 641 
limiting.   642 
 643 
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PRH and response to chemotherapeutics 646 
We have shown that PRH influences resistance to canonical Wnt pathway inhibition by 647 
ICG-001 (an inhibitor of catenin acetylation by CBP). As ICG-001 is reported to be 648 
effective at reducing tumour growth in a mouse model of CCA carcinogenesis (7) and is in 649 
clinical trial for various solid tumours (49), it could become a compound of interest in the 650 
development of novel CCA treatments. Our data suggests that in this case, patient 651 
stratification on the basis of PRH expression may be useful to optimise the clinical benefits of 652 
this drug or its future derivatives. Inhibition of Notch signalling by targeting the γ-secretase 653 
complex is an emerging chemotherapeutic strategy for a variety of cancers (71 clinical trials 654 
undertaken as of 2018 (50)). Our data suggests that as well as driving aberrant Notch 655 
signalling, PRH also determines resistance to Notch inhibition, at least by non-transition state 656 
analogue γ-secretase inhibitors such as DAPT. Our Notch3 knockdown data suggests that 657 
direct targeting of Notch3 (for example, by a blocking antibody or by a small molecule that 658 
specifically interrupts interactions between Notch3-ICD and components of the Notch 659 
transcriptional complex) could be more effective than γ-secretase inhibition. In addition, the 660 
CDK4/6 inhibitor palbociclib strongly inhibited the proliferation of CCA cells in the presence 661 
of exogenous PRH whereas it had significantly less effect on control cells at the same 662 
concentration and PRH knockdown cells were resistant to pablociclib treatment. The effects 663 
of palbociclib on CCA cells are thought to be dependent on Rb expression and it is interesting 664 
to note that primary BECs and immortalised BECs express much lower levels of Rb than 665 
CCA cell lines. Moreover, the effects of palbociclib on CCLP1 cells are largely lost in the 666 
absence of Rb and are abolished when PRH is knocked down.  These data suggest that CCA 667 
cells with high PRH are likely to be highly sensitive to palbociclib treatment and that this 668 
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sensitivity is driven by the presence of PRH in these cells, but also requires Rb. These data 669 
also indicate that at least part of the mechanism by which PRH drives cell proliferation is 670 
likely to be through hyper-activation of CDK4/6. We show that PRH activates cyclin D2 671 
expression via Notch3 and directly represses CDKN2B (p27) and CDKN1B (p15). Moreover 672 
these data suggest that palbociclib or other CDK4/6 specific inhibitors could be especially 673 
effective in the treatment of CCA with high PRH expression levels.  674 
In conclusion, we propose that monitoring PRH and Notch3 levels in patients with high CCA 675 
risk biliary pathologies, either directly by biopsy or indirectly by detection of the protein 676 
products of a set of PRH/Notch3 transcriptional targets (such as cell surface proteins or 677 
secreted proteins) in bile or serum may be a useful diagnostic tool to help predict the 678 
development of CCA in at-risk groups such as PSC patients in the West and liver fluke-679 
infected patients in south-east Asia. In addition, monitoring PRH expression in patients with 680 
CCA may be a useful tool for guiding the choice of chemotherapeutic strategy.  681 
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Figure legends 832 
Figure 1  PRH is over-expressed in cholangiocarcinoma. 833 
 (A) Representative immunostaining of PRH in a cholangiocarcinoma tissue microarray. 834 
Arrowheads mark border tissue biliary epithelium. (B) Quantification of PRH staining 835 
intensity in non-involved bile ducts compared to cholangiocarcinoma. (C) Western blot 836 
showing PRH expression in four human cholangiocarcinoma cell lines, two human primary 837 
biliary epithelial cell isolates and an immortalised cholangiocyte cell line. (D) Growth of 838 
CCLP1 control (34±17 mm
3
) and PRH knockdown tumours (176±27 mm
2
) in nude mouse 839 
xenografts, n=9 per group, p=0.0006 at day 25. (E) Proportion of colony initiating cells in 840 
soft agar for PRH knockdown (3.4±0.4%) and control (7.6±0.5%) CCLP1 cells, n=3, p=0.01. 841 
(F) Final cross-sectional area of colonies in soft agar for PRH knockdown (2063±103 μm
2
) 842 
and control (4783±53 μm
2
) CCLP1 cells, n=3, p=0.002. (G, H) As E,F for AKN1 cells. (I) 843 
Colony formation in soft agar of primary BECs infected with Ad myc-PRH or empty 844 
adenovirus. *denotes p<0.05. 845 
 846 
Figure 2  Effects of PRH manipulation on cholangiocarcinoma cell biology. 847 
 (A) Proliferation of CCLP1 cells stably transfected with PRH shRNA or scrambled control, 848 
n=3, p=0.03. (B) Proliferation of CCLP1 and CCSW1 cells infected with Ad myc-PRH or 849 
empty virus control, n=3, p=0.03 (CCLP1), p=0.02 (CCSW1). (C) Proliferation of AKN1 and 850 
primary BECs over-expressing GFP-PRH-myc (stable) or myc-PRH (transient, 48 hours) 851 
n=3, p=0.003 (AKN1), p=0.006 (BEC). (D) Morphology of CCLP1 cells stably transfected 852 
with PRH shRNA or scrambled control. (E) Western blot showing increased expression of E-853 
cadherin protein after PRH knockdown. Lamin A/C as loading control. (F) Migration of 854 
CCLP1 PRH knockdown cells through transwell filters in a 10% serum gradient, n=3, 855 
p=0.03. (G) Invasion of CCLP1 cells through Matrigel, n=4, p=0.03. (H) Western blotting for 856 
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myc-PRH and EMT associated proteins E-cadherin and Vimentin in AKN1 cells and primary 857 
BECs. (I,J) As G,H for AKN1 cells and primary BECs. *denotes p<0.05. (K) Morphology of 858 
equal numbers of AKN1 cells stably transfected with plasmids expressing GFP (control) or a 859 
GFP-PRH-Myc-tagged fusion protein (GFP-PRH-Myc). The scale bars represent 50 μM in 860 
length. 861 
 862 
Figure 3  RNA sequencing of PRH knockdown and over-expressing CCLP1 cells.  863 
(A) Number of differentially expressed genes (DEGs) detected in PRH knockdown (KD) and 864 
over-expression (OE) experiments, and overlap of these gene sets. (B,C) GSEA using 865 
Hallmark gene sets for PRH OE and KD DEGs. Red bars represent Hallmark sets that are 866 
enriched in both PRH KD and OE DEG lists. FDR – false discovery rate. (D) log2 fold 867 
change of gene expression from PRH OE and KD RNA-seq for BEC related genes. TF - 868 
transcription factor. 869 
 870 
Figure 4  Notch3 expression is regulated by PRH. 871 
(A) Western blot showing Notch3 protein expression in PRH knockdown CCLP1 cells. (B) 872 
NOTCH3 gene expression in CCLP1 and CCSW1 cells infected with Ad myc-PRH, Ad myc-873 
PRH DNA-binding deficient N187A mutant or empty virus control. (C) Western blot for 874 
CCLP1 samples in panel B. (D) Notch3 protein expression correlates with PRH protein 875 
expression in four human cholangiocarcinoma cell lines, two human primary biliary epithelial 876 
cell isolates and an immortalised BEC line. (E) Western blot showing elevated expression of 877 
Notch3 upon PRH over-expression in both AKN1 cells and primary BECs. (F) Western blot 878 
showing increased expression of E-cadherin and reduced expression of PRH proteins after 879 
Notch3 knockdown. Lamin A/C as loading control. (G) Proliferation of CCLP1 cells stably 880 
transfected with Notch3 shRNA or scrambled control, n=3, p=0.04. (H) Morphology of 881 
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CCLP1 cells stably transfected with Notch3 shRNA or scrambled control. (I) DEGs detected 882 
in Notch3 KD compared to PRH KD experiments. Hypergeometric test p=10
-229
 for up-883 
regulated genes and p=10
-31
 for down-regulated genes. (J) Hallmark GSEA of genes 884 
differentially expressed after Notch3 KD. Red bars indicate gene sets that are also enriched 885 
after PRH knockdown. 886 
 887 
Figure 5  Notch3- and PRH-correlated gene sets. 888 
(A) qRT-PCR analysis of genes from CCLP1 cells over-expressing PRH in the presence or 889 
absence of Notch3 shRNA identifying PRH and Notch3 correlated expression signatures. (B) 890 
Western blot analysis of EMT proteins E-cadherin and Vimentin and Cyclin D2 in CCLP1 891 
cells over-expressing myc-PRH in the presence of absence of Notch3 shRNA. (C) 892 
Proliferation of CCLP1 cells over-expressing myc-PRH in the presence or absence of Notch3 893 
shRNA. (D) Hallmark GSEA of Notch3-correlated and PRH correlated gene sets identified 894 
from analysis of RNA-seq data. Red bars indicate gene sets enriched in both PRH- and 895 
Notch3-correlated sets. * denotes p<0.05 after Bonferroni correction, compared to non-896 
targeting shRNA/empty virus control. # denotes no statistically significant difference in the 897 
comparison indicated. (E) Overlap of genes with PRH binding sites determined by ChIP-seq 898 
and genes that are differentially expressed after PRH over-expression determined by RNA-899 
seq in CCLP1 cells. (F) Comparison of the primary motif underlying PRH ChIP-seq peaks 900 
identified using HOMER with the PRH SELEX motif (derived from (38)). (G) RNA-seq and 901 
ChIP-seq tracks of putative direct PRH target DKK1. Red tracks indicate myc-PRH over-902 
expression. (H). RNA-seq and ChIP-seq tracks of putative direct PRH target WNT11. Red 903 
tracks indicate myc-PRH over-expression. 904 
  905 
Figure 6   Regulation of Wnt signalling. 906 
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  (A) TOPFlash TCF/LEF reporter activity in CCLP1 and CCSW1 cells expressing myc-907 
PRH, DNA-binding deficient N187A mutant of myc-PRH and Flag-Notch3-ICD. Inset: 908 
Western blot showing expression of myc-PRH constructs. (B) Representative 909 
immunofluorescence micrographs of CCLP1 PRH knockdown cells stained for E-cadherin 910 
and β-catenin. (C) Western blot of subcellular fractions of CCLP1 PRH knockdown cells.  911 
(D) TOPFlash reporter activity in PRH knockdown CCLP1 cells. (E) TOPFlash reporter 912 
activity in control CCLP1 cells (pcDNA empty) and CCLP1 cells over-expressing E-cadherin 913 
(CDH1) in the presence and absence of myc-PRH expression. Inset: Western blot showing 914 
successful over-expression of E-cadherin. *denotes p<0.05, # denotes no statistically 915 
significant difference. 916 
 917 
Figure 7  Altered sensitivity to therapeutics. 918 
 (A) Proliferation measured by EdU incorporation in CCLP1 cells infected with Ad empty or 919 
Ad myc-PRH and treated with various compounds used at their LD50 as shown (B) Log 920 
sensitivity ratio to compounds from panel A. Drugs with a log ratio >0 are less effective after 921 
PRH over-expression and vice versa. *denotes a log ratio significantly different (p<0.05) 922 
from 0, # denotes no significant difference. (C) Proliferation measured by EdU incorporation 923 
in a panel of CCA cell lines infected with Ad empty or Ad myc-PRH and treated with 924 
palbociclib at their LD50. CCLP1, CCSW and KKU-213 (LD50= 100nM) and KKU-100 925 
(LD50=150nM) as in (A) and presented as log sensitivity ratio as in (B) (*denotes p<0.05, 926 
**denotes p<0.01). (D) Three independent control and Rb knockdown CCLP1 cell 927 
populations were treated with palbociclib at 100nM and cell proliferation measured using 928 
EdU incorporation assays. Inset: Western blot showing successful knockdown of Rb. 929 
*denotes p<0.05, ns denotes no statistically significant difference. (E) Schematic of pathways 930 
affected by PRH in CCA cells and compounds targeting these pathways. Red indicates 931 
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compounds whose efficacy is reduced by PRH over-expression and green indicates 932 
compounds whose efficacy is increased. 933 
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